Editas Q3 net loss $55.7M; second patient dosed in sickle cell trial

Editas Medicine, Inc.

2022-Q3 EPS reported -$2.33 revenue$13,176,000

Net loss $55.7M ($0.81/share) vs $39.1M ($0.57) in Q3 2021.
Collaboration revenue fell to $42K from $6.2M a year ago (2021 had BMS opt-in).
Cash and securities $478.5M, down from $527.6M at June 30; expected to fund into 2024.
Second patient dosed in Phase 1/2 RUBY trial (EDIT-301 for sickle cell); initial data by year-end.
Completed editing for first patient in EDITHAL trial (EDIT-301 for TDT); scheduling dosing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Editas Medicine, Inc. reported the three months ended September 30, 2022 results: revenue $42 thousand, net income $55.7 million, EPS $0.81 per share.

Period: the three months ended September 30, 2022
Revenue: $42 thousand
Net income: $55.7 million
EPS: $0.81 per share
Result: reported results

Exact text from the filing

or $0.81 per share, compared to net loss of $39.1 million, or $0.57 per share, for the same period in 2021. ● Collaboration and other research and development revenues were $42 thousand for the three months ended September 30, 2022, compared to $6.2 million for the same period in 2021. The 2021 period included revenue recognized for an opt-in by Bristol Myers

View on SEC.gov

Browse all earnings releases →

Editas Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-015898

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.